Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS.
BACKGROUND
The purposes of this study were to: (1) compare monthly serum IL-10 in patients with relapsing remitting (RR) multiple sclerosis (MS) and healthy controls, (2) determine the relationship between IL-10 and MRI activity and (3) determine the effect of interferon beta-1a (IFNB-1a) treatment on IL-10 levels.


RESULTS
Median serum IL-10 levels were lower in untreated RRMS (185.5 pg/ml) compared to controls (438.5 pg/ml) (P=0.19). Serum levels of IL-10 did not appear to predict the appearance of new gadolinium-enhancing (Gd+) lesions concurrently or 1 month thereafter. However, IL-10 levels were more likely to be elevated the month during which Gd+ lesions resolved (OR=3.14, P=0.01). Median IL-10 levels were lower during IFNB-1a treatment (P=0.01).


CONCLUSIONS
These observations suggest a relationship between serum IL-10 levels and resolution of abnormal vascular permeability in new lesions.
Waubant
E
E
UCSF/Mt Zion Multiple Sclerosis Center, 1701 Divisadero Street, San Francisco, CA 94115, USA. emmanuelle.waubant@pls.ap-hop-paris.fr
Gee
L
L
Bacchetti
P
P
Sloan
R
R
Cotleur
A
A
Rudick
R
R
Goodkin
D
D
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000097:blood*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D016753:Interleukin-10; D016899:Interferon-beta; D000068556:Interferon beta-1a